MWNA
KZR

Marshall Wace North America’s Kezar Life Sciences KZR Stock Holding History

Marshall Wace North America’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,583
Closed -$1.84M – 1564
2018
Q3 		$1.84M Sell
8,583
-2,475
-22% -$432K 0.01% 503
2018
Q2 		$1.91M Buy
+11,058
New +$1.93M 0.01% 777

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Marshall Wace North America's KZR Position: Q4 2018 in Review

Marshall Wace North America sold out of Kezar Life Sciences (KZR) in Q4 2018, closing a stake of 8,583 shares — an estimated $1.84M sold.

Marshall Wace North America first reported a position in KZR in Q2 2018 and held it in 2 quarters. The position peaked at $1.91M in Q2 2018. 39 funds tracked by Wall St. Rank hold KZR as of Q4 2018.

  • Marshall Wace North America reported no remaining Kezar Life Sciences position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 8,583 Kezar Life Sciences shares in Q4 2018, an estimated $1.84M.
  • Marshall Wace North America first reported a position in Kezar Life Sciences in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Kezar Life Sciences position peaked at $1.91M in Q2 2018.
  • 39 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.